Targeting a specific protein complex to improve treatment for estrogen receptor positive breast cancer
Targeting Oncogenic PELP1/SRC-3 Signaling Complexes in ER+ Breast Cancer
This study is looking at how specific proteins might help estrogen receptor positive breast cancer grow and resist treatment, with the goal of finding new ways to improve care for patients facing this type of cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-11009067 on NIH RePORTER |
What this research studies
This research focuses on understanding how certain protein complexes, specifically PELP1 and SRC-3, contribute to the progression of estrogen receptor positive (ER+) breast cancer. The study aims to investigate the mechanisms by which these proteins promote cancer stem cell characteristics and resistance to current therapies. By targeting these complexes, the research seeks to develop new strategies to overcome treatment resistance and improve outcomes for patients with advanced ER+ breast cancer. Patients may benefit from novel therapeutic approaches that could emerge from this work.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with estrogen receptor positive breast cancer, particularly those who have experienced treatment resistance.
Not a fit: Patients with non-estrogen receptor positive breast cancer or those who are not currently undergoing treatment may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with advanced ER+ breast cancer who currently have limited options.
How similar studies have performed: Other research has shown promise in targeting similar oncogenic pathways in breast cancer, indicating that this approach may yield beneficial results.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Truong, Thu Ha — University of Minnesota
- Study coordinator: Truong, Thu Ha
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.